Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTA01 for High-Risk COVID-19 Outpatients
NCT04709328Phase 3Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of upanovimab in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
upanovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04709328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709328.